glypican-1 Antibody (9E9): sc-101826

glypican-1 Antibody (9E9) is a mouse monoclonal IgG1 antibody that detects glypican-1 in mouse, rat, and human samples through applications such as western blotting (WB) and immunofluorescence (IF). Glypican-1, a member of the glycosylphosphatidylinositol-anchored cell surface heparan sulfate proteoglycans, plays a crucial role in various biological processes, including cell adhesion, migration, and the modulation of growth factor activities. Notably, anti-glypican-1 antibody (9E9) recognizes a protein involved in the interaction with fibroblast growth factors (FGFs), such as FGF-1, FGF-2, and FGF-7, which are essential for cellular signaling and development. Glypican-1′s heparan sulfate chains facilitate specific binding to vascular endothelial growth factor 165 (VEGF165), acting as an extracellular chaperone that restores receptor binding ability after oxidative stress. This function is particularly important in the context of hematopoietic stem and progenitor cell maintenance, as glypican-1 present on marrow stromal cells may support their development. Furthermore, elevated levels of glypican-1 in human pancreatic cancer cells compared to normal pancreatic cells suggest a significant role in the tumor microenvironment and response to mitogenic stimuli, such as FGF-2. The gene encoding human glypican-1 is located on chromosome 2q37.3, highlighting genetic significance in health and disease. Glypican-1 monoclonal antibody (9E9) serves as an invaluable tool for researchers investigating the multifaceted roles of glypican-1 in various biological contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

glypican-1 Antibody (9E9) References:

1. Glypican-1-antibody-conjugated Gd-Au nanoclusters for FI/MRI dual-modal targeted detection of pancreatic cancer.  |  Huang, X., et al. 2018. Int J Nanomedicine. 13: 2585-2599. PMID: 29750031
2. Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.  |  Chiu, K., et al. 2018. Mod Pathol. 31: 1400-1403. PMID: 29785020
3. The glycocalyx core protein Glypican 1 protects vessel wall endothelial cells from stiffness-mediated dysfunction and disease.  |  Mahmoud, M., et al. 2021. Cardiovasc Res. 117: 1592-1605. PMID: 32647868
4. Glypican-1 Overexpression in Different Types of Breast Cancers.  |  Alshammari, FOFO., et al. 2021. Onco Targets Ther. 14: 4309-4318. PMID: 34366675
5. Glypican 1 and syndecan 1 differently regulate noradrenergic hypertension development: Focus on IP3R and calcium.  |  Potje, SR., et al. 2021. Pharmacol Res. 172: 105813. PMID: 34411733
6. Role of glypican-1 in regulating multiple cellular signaling pathways.  |  Pan, J. and Ho, M. 2021. Am J Physiol Cell Physiol. 321: C846-C858. PMID: 34550795
7. Glypican-1 drives unconventional secretion of fibroblast growth factor 2.  |  Sparn, C., et al. 2022. Elife. 11: PMID: 35348113
8. Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma.  |  Zhao, J., et al. 2022. Front Oncol. 12: 992929. PMID: 36313694
9. Glypican 1 promotes proliferation and migration in esophagogastric adenocarcinoma via activating AKT/GSK/β-catenin pathway.  |  Pratap, A., et al. 2022. J Gastrointest Oncol. 13: 2082-2104. PMID: 36388647
10. Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma.  |  Uchida, S., et al. 2024. Neoplasia. 50: 100982. PMID: 38417223

The preferred glypican-1 antibody is glypican-1 Antibody (A-10): sc-365000.